Grant: Project Grant
University of Toronto
$278,971.00
Sex differences in the risk of recurrent venous thromboembolism: testing an epigenetic hypothesis
EF 2018-19
Résumé
Venous thromboembolism (VTE) is a blood clot that forms in a vein. VTE is a common, lethal, costly, yet treatable condition. There are effective drugs to prevent VTE but they increase the risk of bleeding. Our team has long-term interest in understanding what causes VTE, and how to prevent and treat VTE. We argue that we need to understand how DNA and the way it is packaged and 'read' (i.e. the epigenetic 'code') leads to disease in order to better prevent and manage VTE. The epigenetic code is the intermediate player linking a person's environment and his/her genetic make up.
An individual's sex is an important variable on how the genetic and epigenetic codes impact a person's risk to VTE, and how he or she responds to treatment. In particular, we are intrigued by the fact that men and women have a similar risk of developing a first VTE, but men have more than twice the risk of a subsequent VTE after a 'blood thinner' drug treatment is stopped. We propose that sex-specific epigenetic marks underlie the protective effects against subsequent VTE observed in women after treatment with a 'blood thinner'.
We will analyze patients' blood samples, biological and clinical data, and perform lab experiments, to understand the biology behind sex differences in the response to VTE treatment. This will be the basis of new tests that will ultimately improve the standard of care received by men and women after a first VTE event. Given the importance and the risk of using 'blood thinners' to manage patients following a VTE, being able to predict who will benefit the most from such drugs and who can safely discontinue their use after initial treatment are of major importance in caring for these patients. This will also inform on novel intervention targets that could reverse the risk of VTE.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
389767
Name
Gagnon France
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Clinical
Prcname2
Gender, Sex & Health
Projecttitle
Sex differences in the risk of recurrent venous thromboembolism: testing an epigenetic hypothesis
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$278,971
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Blood Epigenetic Markers; Clinical Decision Rules; Epidemiology; Sex Differences; Venous Thrombosis
Abstract
Venous thromboembolism (VTE) is a blood clot that forms in a vein. VTE is a common, lethal, costly, yet treatable condition. There are effective drugs to prevent VTE but they increase the risk of bleeding. Our team has long-term interest in understanding what causes VTE, and how to prevent and treat VTE. We argue that we need to understand how DNA and the way it is packaged and 'read' (i.e. the epigenetic 'code') leads to disease in order to better prevent and manage VTE. The epigenetic code is the intermediate player linking a person's environment and his/her genetic make up.
An individual's sex is an important variable on how the genetic and epigenetic codes impact a person's risk to VTE, and how he or she responds to treatment. In particular, we are intrigued by the fact that men and women have a similar risk of developing a first VTE, but men have more than twice the risk of a subsequent VTE after a 'blood thinner' drug treatment is stopped. We propose that sex-specific epigenetic marks underlie the protective effects against subsequent VTE observed in women after treatment with a 'blood thinner'.
We will analyze patients' blood samples, biological and clinical data, and perform lab experiments, to understand the biology behind sex differences in the response to VTE treatment. This will be the basis of new tests that will ultimately improve the standard of care received by men and women after a first VTE event. Given the importance and the risk of using 'blood thinners' to manage patients following a VTE, being able to predict who will benefit the most from such drugs and who can safely discontinue their use after initial treatment are of major importance in caring for these patients. This will also inform on novel intervention targets that could reverse the risk of VTE.
Competitiondate
201809
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gagnon, France; Rodger, Marc A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $278,971~ $0~